Alopecia Areata trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Alopecia Areata. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month1 study across 1 company, in the next 180 days.
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataNCT07029711For US and Countries Following US Analysis Plan: Response based on achieving an absolute Severity of Alopecia Tool (SALT) score ≤20. | Phase 3 | Active, not recruiting | 2026-12-02 | in 104 d | 2026-06-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Alopecia Areata
most recently updated first37 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataNCT07772492Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20, defined as less than or equal to 20% scalp hair loss. | Phase 3 | Not yet recruiting | Drug: Upadacitinib, Placebo | Severe Alopecia Areata | 300 | 2026-08-30 | Mar 2032 | ≤ 2,050 d | 2026-08-19 |
| PFE | Pfizer | $155.3B | A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia AreataNCT06873945Part 1: Percentage of participants with absolute Severity of Alopecia Tool (SALT) score less than or equal to 20 | Phase 3 | Recruiting | Drug: Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg | Alopecia Areata | 1,330 | 2025-04-01 | 2028-03-19 | in 577 d | 2026-08-13 |
| SNY | Sanofi | — | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia AreataNCT06444451Change from baseline in Severity of Alopecia Tool (SALT) score at Week 36 | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision; the decision is not related to any safety concern | Drug: Amlitelimab, Placebo | Alopecia Areata | 166 | 2024-06-06 | 2025-09-24actual | — | 2026-08-10 |
| PFE | Pfizer | $155.3B | Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the USNCT07226531observationalPatient demographics characteristics: race | — | Completed | Drug: Ritlecitinib | Alopecia Areata | 300 | 2025-12-22 | 2026-03-06actual | — | 2026-08-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)NCT07533006Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Less than or Equal to (≤) 20 | Phase 2 | Recruiting | Drug: LY4005130, Placebo | Alopecia Areata | 60 | 2026-04-14 | Jun 2027 | ≤ 314 d | 2026-08-06 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataNCT06012240Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20 | Phase 3 | Recruiting | Drug: Upadacitinib, Placebo | Alopecia Areata | 1,500 | 2023-10-11 | Apr 2030 | ≤ 1,349 d | 2026-08-03 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia AreataNCT07023302Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 10 | Phase 3 | Active, not recruiting | Drug: Upadacitinib, Upadacitinib Placebo | Alopecia Areata | 125 | 2025-06-19 | Feb 2029 | ≤ 923 d | 2026-07-30 |
| PFE | Pfizer | $155.3B | A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia AreataNCT07733765Difference in the proportion of Severity of Alopecia Tool (SALT) 0 responders at Week 24 between ritlecitinib 50 mg QD versus placebo | Phase 3 | Not yet recruiting | Drug: Ritlecitinib 100 mg, Ritlecitinib 50 mg · Other: Placebo | Alopecia Areata | 336 | 2026-07-31 | 2028-04-27 | in 616 d | 2026-07-29 |
| PFE | Pfizer | $155.3B | Characterization And Clinical Outcomes of AA Patients Treated With RitlecitinibNCT06531109observationalPercentage change from baseline in Severity of Alopecia Tool (SALT) score at week 24 | — | Recruiting | Drug: Ritlecitinib | Alopecia Areata | 450 | 2024-08-07 | 2028-04-15 | in 604 d | 2026-07-23 |
| NKTR | Nektar Therapeutics | $2.5B | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)NCT06340360Percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 36 | Phase 2 | Active, not recruiting | Drug: Rezpegaldesleukin, Placebo | Alopecia Areata | 94 | 2024-04-02 | 2025-11-26actual | — | 2026-07-10 |
| PFE | Pfizer | $155.3B | A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataNCT07029711For US and Countries Following US Analysis Plan: Response based on achieving an absolute Severity of Alopecia Tool (SALT) score ≤20. | Phase 3 | Active, not recruiting | Drug: Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo | Severe Alopecia Areata | 208 | 2025-07-31 | 2026-12-02 | in 104 d | 2026-06-17 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world SettingsNCT07200128observational% of patients for whom their clinician was "satisfied" with current control of alopecia areata | — | Completed | Drug: Ritlecitinib | Severe Alopecia Areata | 123 | 2025-02-03 | 2025-05-30actual | — | 2026-06-10 |
| ALM.MC | Almirall, S.A. | $2.2B | A Study of LAD603 in Adults With Alopecia AreataNCT07311564Percent Change from Baseline in the Severity of Alopecia Tool (SALT) Score | Phase 2 | Recruiting | Drug: LAD603 · Other: Placebo | Alopecia Areata | 136 | 2025-12-17 | 2027-06-23 | in 307 d | 2026-05-20 |
| PFE | Pfizer | $155.3B | A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.NCT07152119observationalFrequency and proportion of AEs/ADRs | — | Recruiting | Drug: Litfulo | Severe Alopecia Areata | 3,000 | 2025-08-27 | 2030-03-23 | in 1,311 d | 2026-05-18 |
| QTTB | Q32 Bio Inc. | $455M | A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)NCT06018428Part A: Mean relative percent change in SALT score | Phase 2 | Active, not recruiting | Drug: bempikibart (ADX-914) | Alopecia Areata | 75 | 2023-09-12 | Jun 2026 | — | 2026-05-08 |
| PFE | Pfizer | $155.3B | A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.NCT07029828Incidence of treatment-emergent adverse events (AEs). | Phase 3 | Recruiting | Drug: Ritlecitinib higher dose, Ritlecitinib lower dose | Severe Alopecia Areata | 140 | 2025-09-10 | 2030-06-26 | in 1,406 d | 2026-04-28 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia AreataNCT03570749results2025-10-01Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 - Phase 3 | Phase 2/3 | Completed | Drug: Baricitinib, Placebo | Alopecia Areata | 784 | 2018-09-24 | 2021-02-02actual | — | 2026-04-16 |
| PFE | Pfizer | $155.3B | Long-Term PF-06651600 for the Treatment of Alopecia AreataNCT04006457results2025-08-14Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit | Phase 3 | Completed | Drug: PF-06651600 · Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine | Alopecia Areata | 1,057 | 2019-07-18 | 2024-06-25actual | — | 2026-04-09 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia AreataNCT03899259results2024-05-14Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 | Phase 3 | Completed | Drug: Baricitinib, Placebo | Alopecia Areata | 606 | 2019-07-08 | 2021-01-24actual | — | 2026-04-07 |
| PFE | Pfizer | $155.3B | Litfulo Capsules Special InvestigationNCT06279221observationalProportion of participants with adverse events (AEs) | — | Active, not recruiting | Drug: LITFULO | Alopecia Areata | 487 | 2024-03-01 | 2030-04-24 | in 1,343 d | 2026-03-02 |
| ABBV | AbbVie | $457.5B | A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis SuppurativaNCT07136467observationalAlopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only | — | Recruiting | — | Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa | 2,795 | 2025-09-02 | Aug 2027 | ≤ 376 d | 2026-02-13 |
| FBRX | Forte Biosciences, Inc. | $1.6B | A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.NCT07205159Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) | Phase 1 | Recruiting | Drug: FB102, Placebo | Alopecia Areata | 32 | 2025-10-23 | 2027-03-10 | in 202 d | 2025-11-20 |
| PFE | Pfizer | $155.3B | Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)NCT05522556expanded access | — | Available | Drug: Ritlecitinib | Alopecia Areata | — | — | — | — | 2025-11-18 |
| PFE | Pfizer | $155.3B | PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATANCT04517864results2022-12-28Change From Baseline in I-V Interwave Latency on Brainstem Auditory Evoked Potentials (BAEP) at a Stimulus Intensity of 80 Decibels (dB) From the Right Side at Month 9 | Phase 2 | Terminatedsponsor's stated reason: For business reasons | Drug: PF-06651600, Placebo | Alopecia Areata | 71 | 2020-09-15 | 2022-01-04actual | — | 2025-07-11 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia AreataNCT05556265results2025-02-28Change From Baseline in Severity of Alopecia Tool Score at Week 24 in Placebo-Controlled Treatment Period | Phase 2 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: Deucravacitinib · Other: Placebo | Alopecia Areata | 94 | 2022-11-08 | 2024-01-06actual | — | 2025-05-31 |
| EQ | Equillium | $149M | Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia AreataNCT05589610results2025-04-10Number of Treatment Emergent Adverse Events | Phase 2 | Completed | Drug: EQ101 | Alopecia Areata, Alopecia, Alopecia Totalis, Alopecia Universalis | 36 | 2022-12-19 | 2024-03-26actual | — | 2025-04-10 |
| AMGN | Amgen | $229.9B | Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia AreataNCT05368103results2025-01-07Percent Change From Baseline in SALT Score at Week 24 | Phase 2 | Completed | Biological: Daxdilimab | Alopecia Areata | 30 | 2022-04-27 | 2023-08-07actual | — | 2025-01-07 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of AgeNCT05650333results2024-10-08Area Under the Plasma Concentration-Time Profile Over the Dosing Interval of 24 Hours, at Steady State (AUC24ss/AUCtau) of Ritlecitinib on Day 7 | Phase 1 | Completed | Drug: Ritlecitinib 20 mg | Alopecia Areata | 15 | 2023-03-02 | 2023-08-11actual | — | 2024-10-08 |
| PFE | Pfizer | $155.3B | Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia AreataNCT04556734results2024-06-26Percent Change From Baseline in Severity of Alopecia Tool I (SALT I) at Week 24: DB Treatment Period | Phase 2 | Completed | Drug: Etrasimod, Etrasimod, Placebo | Alopecia Areata | 80 | 2020-07-29 | 2023-06-07actual | — | 2024-06-26 |
| EQ | Equillium | $149M | Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia AreataNCT03532958Change from baseline using the Severity of Alopecia Tool (SALT) score | Phase 2 | Withdrawnsponsor's stated reason: Transfer of study sponsor | Drug: BNZ-1, Normal saline | Alopecia Areata, Alopecia Totalis, Alopecia Universalis | 0 | Oct 2021 | Nov 2022 | — | 2022-09-16 |
| ANAB | AnaptysBio, Inc. | $1.7B | A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia AreataNCT05205070Change from baseline in Severity of Alopecia Tool (SALT) score at Week 24 | Phase 2 | Unknown status | Biological: Rosnilimab, Placebo | Alopecia Areata | 45 | 2021-12-22 | 2023-01-19 | — | 2022-05-10 |
| PFE | Pfizer | $155.3B | PF-06651600 for the Treatment of Alopecia AreataNCT03732807results2022-02-24Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 | Phase 2/3 | Completed | Drug: PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2, PF-06651600 Maintenance Dose #3, Placebo | Alopecia Areata | 718 | 2018-12-03 | 2020-12-31actual | — | 2022-02-24 |
| INCY | Incyte Corporation | $24.7B | A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)NCT02553330results2020-12-16Part A: Percentage of Participants Achieving a ≥ 50% Improvement in SALT50 Response in Terminal Hair (Pigmented and Nonpigmented). | Phase 2 | Terminatedsponsor's stated reason: The study was terminated early based on the results of a planned interim analysis. | Drug: Placebo Cream, Ruxolitinib Phosphate Cream | Alopecia Areata | 90 | 2015-11-18 | 2017-10-03actual | — | 2020-12-16 |
| ACRS | Aclaris Therapeutics, Inc. | $928M | ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)NCT03759340results2020-09-17Change in the Severity of Alopecia Tool (SALT) Score | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: ATI 502 0.46% Topical Solution | Alopecia Areata, Alopecia Universalis, Alopecia Totalis | 56 | 2019-01-15 | 2019-09-11actual | — | 2020-10-06 |
| ACRS | Aclaris Therapeutics, Inc. | $928M | A Study of ATI-50002 Topical Solution for the Treatment of Alopecia AreataNCT03354637results2020-06-05Percent Change From Baseline in the Severity of Alopecia Tool Score at Week 24 | Phase 2 | Terminatedsponsor's stated reason: The double-blind primary endpoint was not met. Open Label Extension period halted as a result. | Drug: ATI-50002 high dose, ATI-50002 low dose, Placebo | Alopecia Areata | 129 | 2017-11-29 | 2019-04-18actual | — | 2020-06-05 |
| PFE | Pfizer | $155.3B | Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia AreataNCT02974868results2020-05-26Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 | Phase 2 | Completed | Drug: PF-06651600, PF-06700841, Placebo | Alopecia Areata | 142 | 2016-12-15 | 2019-05-15actual | — | 2020-05-26 |
| ACRS | Aclaris Therapeutics, Inc. | $928M | Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia AreataNCT03551821results2019-12-11Clinician's Eyebrow Assessment | Phase 2 | Completed | Drug: ATI-50002 | Alopecia Areata, Alopecia Totalis, Alopecia Universalis | 1 | 2018-04-11 | 2018-11-06actual | — | 2019-12-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Alopecia Areata is matched — 2 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Alopecia Areata
- Severe Alopecia Areata
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Alopecia Areata” (a text search, wider than this page)